返回 
加入收藏
中药调控Nrf2信号通路改善胆汁淤积性肝病的研究进展
x
请在关注微信后，向客服人员索取文件
| 篇名： | 中药调控Nrf2信号通路改善胆汁淤积性肝病的研究进展 |
| TITLE： | Research progress on the regulation of the Nrf2 signaling pathway by traditional Chinese medicine in ameliorating cholestatic liver disease |
| 摘要： | 胆汁淤积性肝病（CLD）的发生与胆汁酸稳态失衡、氧化应激、炎症反应、线粒体损伤及肝纤维化等密切相关。核转录因子红系2相关因子2（Nrf2）可调控抗氧化、解毒及胆汁酸转运相关分子表达，并与法尼醇X受体（FXR）、沉默信息调节因子1/AMP活化的蛋白激酶、核因子κB等信号通路共同参与CLD的发生发展。本文综述了Nrf2在CLD发生发展中的作用，以及中药活性成分和复方/中成药调控Nrf2干预CLD的研究进展。结果显示，萜类、皂苷类、黄酮类、多糖类等中药活性成分，以及清热利湿、疏肝利胆和扶正护肝类复方/中成药，可通过调控Nrf2相关信号通路，改善胆汁酸代谢与转运，减轻氧化应激、炎症反应及肝纤维化。现有研究仍主要依据Nrf2表达、核转位及下游分子表达变化进行判断，对Nrf2与FXR等信号通路间的调控关系及复方多成分协同机制的认识尚不充分。后续研究可加强基因干预与功能验证，借助肝或胆管类器官、共培养体系等手段，结合胆汁酸谱及多组学分析，进一步阐明中药调控Nrf2改善CLD的作用机制。 |
| ABSTRACT： | Cholestatic liver disease （CLD） is closely associated with bile acid homeostasis imbalance， oxidative stress， inflammatory responses， mitochondrial damage， and hepatic fibrosis. Nuclear factor-erythroid 2-related factor 2 （Nrf2） can regulate molecules related to antioxidation， detoxification， and bile acid transport， and together with signaling pathways such as farnesoid X receptor （FXR）， silent information regulator 1/AMP-activated protein kinase， and nuclear factor-κB， participates in the development and progression of CLD. This review summarizes the role of Nrf2 in the development and progression of CLD， as well as the research progress on traditional Chinese medicine （TCM） active constituents and formulas/Chinese patent medicine in regulating Nrf2 for the intervention of CLD. The results indicate that TCM active constituents such as terpenoids， saponins， flavonoids， and polysaccharides， as well as formulas/Chinese patent medicine with the effects of heat-clearing and dampness-draining， liver-soothing and choleretic-promoting， and body-strengthening and liver-protecting， can improve bile acid metabolism and transport and alleviate oxidative stress， inflammatory responses， and hepatic fibrosis by regulating Nrf2-related signaling pathways. However， existing studies still primarily judge based on Nrf2 expression， nuclear translocation， and downstream molecular expression changes， and the understanding of the regulatory relationship between Nrf2 and signaling pathways such as FXR， as well as the synergistic mechanisms of multiple constituents in formulas， remains insufficient. Future studies can strengthen gene intervention and functional validation， utilize liver or bile duct organoids， co-culture systems， and other approaches， and combine bile acid profiling and multi-omics analysis to further elucidate the mechanism by which TCM regulates Nrf2 to ameliorate CLD. |
| 期刊： | 2026年第37卷第18期 |
| 作者： | 毕晓飞；黄洁瑶；黄娟；孙秋艳；方伟；肖亚平 |
| AUTHORS： | BI Xiaofei，HUANG Jieyao，HUANG Juan，SUN Qiuyan，FANG Wei，XIAO Yaping |
| 关键字： | 胆汁淤积性肝病;核转录因子红系2相关因子2;中药活性成分;中药复方;中成药;氧化应激 |
| KEYWORDS： | cholestatic liver disease;nuclear factor-erythroid 2-related factor 2;TCM active constituents;TCM formulas;Chinese patent medicine;Oxidative stress |
| 阅读数： | 6 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
